Literature DB >> 18246049

Whole genome SNP arrays as a potential diagnostic tool for the detection of characteristic chromosomal aberrations in renal epithelial tumors.

Federico A Monzon1, Jill M Hagenkord, Maureen A Lyons-Weiler, Jyoti P Balani, Anil V Parwani, Christin M Sciulli, Jia Li, Uma R Chandran, Sheldon I Bastacky, Rajiv Dhir.   

Abstract

Renal tumors with complex or unusual morphology require extensive workup for accurate classification. Chromosomal aberrations that define subtypes of renal epithelial neoplasms have been reported. We explored if whole-genome chromosome copy number and loss-of-heterozygosity analysis with single nucleotide polymorphism (SNP) arrays can be used to identify these aberrations and classify renal epithelial tumors. We analyzed 20 paraffin-embedded tissues representing clear cell, papillary renal and chromophobe renal cell carcinoma, as well as oncocytoma with Affymetrix GeneChip 10K 2.0 Mapping arrays. SNP array results were in concordance with known genetic aberrations for each renal tumor subtype. Additional chromosomal aberrations were detected in all renal cell tumor types. The unique patterns allowed 19 out of 20 tumors to be readily categorized by their chromosomal copy number aberrations. One papillary renal cell carcinoma type 2 did not show the characteristic 7/17 trisomies. Clustering using the median copy number of each chromosomal arm correlated with histological class when using a restricted set of chromosomes. In addition, three morphologically challenging tumors were analyzed to explore the potential clinical utility of this method. In these cases, the SNP array-based copy number evaluation yielded information with potential clinical value. These results show that SNP arrays can detect characteristic chromosomal aberrations in paraffin-embedded renal tumors, and thus offer a high-resolution, genome-wide method that can be used as an ancillary study for classification and potentially for prognostic stratification of these tumors.

Entities:  

Mesh:

Year:  2008        PMID: 18246049     DOI: 10.1038/modpathol.2008.20

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  20 in total

1.  Durable remission of metastatic renal cell carcinoma with gemcitabine and capecitabine after failure of targeted therapy.

Authors:  Stephen L Richey; Chaan Ng; Zita D Lim; Eric Jonasch; Nizar M Tannir
Journal:  J Clin Oncol       Date:  2010-12-20       Impact factor: 44.544

2.  Histopathologic subtype-specific genomic profiles of renal cell carcinomas identified by high-resolution whole-genome single nucleotide polymorphism array analysis.

Authors:  Akira Yokomizo; Ken Yamamoto; Kenji Furuno; Masaki Shiota; Katsunori Tatsugami; Kentaro Kuroiwa; Seiji Naito
Journal:  Oncol Lett       Date:  2010-09-23       Impact factor: 2.967

3.  Chromosome 14q loss defines a molecular subtype of clear-cell renal cell carcinoma associated with poor prognosis.

Authors:  Federico A Monzon; Karla Alvarez; Lief Peterson; Luan Truong; Robert J Amato; Joan Hernandez-McClain; Nizar Tannir; Anil V Parwani; Eric Jonasch
Journal:  Mod Pathol       Date:  2011-07-01       Impact factor: 7.842

4.  Spectrum of diverse genomic alterations define non-clear cell renal carcinoma subtypes.

Authors:  Steffen Durinck; Eric W Stawiski; Andrea Pavía-Jiménez; Zora Modrusan; Payal Kapur; Bijay S Jaiswal; Na Zhang; Vanina Toffessi-Tcheuyap; Thong T Nguyen; Kanika Bajaj Pahuja; Ying-Jiun Chen; Sadia Saleem; Subhra Chaudhuri; Sherry Heldens; Marlena Jackson; Samuel Peña-Llopis; Joseph Guillory; Karen Toy; Connie Ha; Corissa J Harris; Eboni Holloman; Haley M Hill; Jeremy Stinson; Celina Sanchez Rivers; Vasantharajan Janakiraman; Weiru Wang; Lisa N Kinch; Nick V Grishin; Peter M Haverty; Bernard Chow; Julian S Gehring; Jens Reeder; Gregoire Pau; Thomas D Wu; Vitaly Margulis; Yair Lotan; Arthur Sagalowsky; Ivan Pedrosa; Frederic J de Sauvage; James Brugarolas; Somasekar Seshagiri
Journal:  Nat Genet       Date:  2014-11-17       Impact factor: 38.330

5.  Genomic imbalances in benign metastasizing leiomyoma: characterization by conventional karyotypic, fluorescence in situ hybridization, and whole genome SNP array analysis.

Authors:  Joslin M Bowen; Justin M Cates; Shera Kash; Doha Itani; Adriana Gonzalez; Dali Huang; Andre Oliveira; Julia A Bridge
Journal:  Cancer Genet       Date:  2012-05

6.  Strength of molecular cytogenetic analyses for adjusting the diagnosis of renal cell carcinomas with both clear cells and papillary features: a study of three cases.

Authors:  Juliette Haudebourg; Benjamin Hoch; Thibault Fabas; Nathalie Cardot-Leccia; Fanny Burel-Vandenbos; Annick Vieillefond; Jean Amiel; Jean-François Michiels; Florence Pedeutour
Journal:  Virchows Arch       Date:  2010-06-22       Impact factor: 4.064

7.  Hybrid oncocytic/chromophobe renal cell tumours do not display genomic features of chromophobe renal cell carcinomas.

Authors:  Nicolas Poté; Annick Vieillefond; Jérôme Couturier; Sandrine Arrufat; Isabelle Metzger; Nicolas B Delongchamps; Philippe Camparo; Florence Mège-Lechevallier; Vincent Molinié; Mathilde Sibony
Journal:  Virchows Arch       Date:  2013-05-25       Impact factor: 4.064

8.  Contemporary epidemiology of renal cell cancer.

Authors:  Wong-Ho Chow; Susan S Devesa
Journal:  Cancer J       Date:  2008 Sep-Oct       Impact factor: 3.360

9.  Genomic profiling of plasmablastic lymphoma using array comparative genomic hybridization (aCGH): revealing significant overlapping genomic lesions with diffuse large B-cell lymphoma.

Authors:  Chung-Che Chang; Xiaobo Zhou; Jesalyn J Taylor; Wan-Ting Huang; Xianwen Ren; Federico Monzon; Yongdong Feng; Pulivarthi H Rao; Xin-Yan Lu; Facchetti Fabio; Susan Hilsenbeck; Chad J Creighton; Elaine S Jaffe; Ching-Ching Lau
Journal:  J Hematol Oncol       Date:  2009-11-12       Impact factor: 17.388

Review 10.  From bench to bedside: current and future applications of molecular profiling in renal cell carcinoma.

Authors:  Androu Arsanious; Georg A Bjarnason; George M Yousef
Journal:  Mol Cancer       Date:  2009-03-17       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.